Top

Cancer Chemotherapy and Pharmacology

Published in:

01-06-2018 | Original Article

Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis

Authors: Sakura Iizumi, Atsuo Takashima, Kentaro Sakamaki, Satoshi Morita, Narikazu Boku

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2018

Abstract

Purpose

We conducted a systematic review and meta-analysis on survival impact of post-progression chemotherapy (post-Cx) after first-line chemotherapy (1st-Cx) and after second-line chemotherapy (2nd-Cx), and survival benefit of third-line chemotherapy (3rd-Cx) for advanced gastric cancer (AGC).

Methods

Phase III trials of systemic chemotherapy for AGC published in English between 2005 and 2015 or presented at annual meetings of ASCO or ESMO between 2013 and 2015 were searched. Numbers of patients, types of chemotherapy, patient baseline, proportion of patients receiving post-Cx (post-Cx%), median progression-free survival (mPFS), and median overall survival (mOS) of each treatment arm were surveyed; trials not reporting these parameters were excluded. Median post-progression survival (mPPS) was calculated as the difference between mOS and mPFS. Weighted Spearman’s correlation coefficients between post-Cx% and survival outcomes (mOS and mPPS) were calculated. The effect of post-Cx% on survival outcomes adjusted for the types of chemotherapy and patient characteristics was evaluated by meta-regression.

Results

Overall, 25 phase III trials of AGC were selected: 15 trials with 31 arms for 1st-Cx, and 10 trials with 16 arms for 2nd-Cx. Weighted Spearman’s correlation coefficients for post-Cx% and mOS/mPPS were 0.520/0.739 for 1st-Cx, and 0.767/0.823 for 2nd-Cx. Meta-regression analyses adjusting for types of chemotherapy, age, and PS showed that a 10% increase in post-Cx% was associated with prolongation of mOS by 1.033 months for 1st-Cx and 0.344 months for 2nd-Cx.

Conclusions

Post-Cx% both after 1st-Cx and 2nd-Cx were correlated with mOS/mPPS, suggesting a survival benefit of 3rd-Cx in addition to that of 2nd-Cx for AGC.

Available only for authorised users

Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359-386. https://doi.org/10.1002/ijc.29210 CrossRef

Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24(18):2903–2909. https://doi.org/10.1200/jco.2005.05.0245 CrossRefPubMed

Thuss-Patience PC, Kretzschmar A, Bichev D et al (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47(15):2306–2314. https://doi.org/10.1016/j.ejca.2011.06.002 CrossRefPubMed

Kang JH, Lee SI, Lim do H et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30(13):1513–1518. https://doi.org/10.1200/jco.2011.39.4585 CrossRefPubMed

Ford HE, Marshall A, Bridgewater JA et al (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 15(1):78–86. https://doi.org/10.1016/s1470-2045(13)70549-7 CrossRefPubMed

Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11):1224–1235. https://doi.org/10.1016/s1470-2045(14)70420-6 CrossRefPubMed

Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383(9911):31–39. https://doi.org/10.1016/s0140-6736(13)61719-5 CrossRefPubMed

Hironaka S, Ueda S, Yasui H et al (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31(35):4438–4444. https://doi.org/10.1200/jco.2012.48.5805 CrossRefPubMed

Shitara K, Matsuo K, Muro K, Doi T, Ohtsu A (2014) Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer. Gastric Cancer 17(2):362–370. https://doi.org/10.1007/s10120-013-0274-6 CrossRefPubMed

10.

Shitara K, Muro K, Shimada Y et al (2016) Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer 19(3):927–938. https://doi.org/10.1007/s10120-015-0559-z CrossRefPubMed

11.

Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461–2471. https://doi.org/10.1016/S0140-6736(17)31827-5 CrossRefPubMed

12.

Takashima A, Iizumi S, Boku N (2017) Survival after failure of first-line chemotherapy in advanced gastric cancer patients: differences between Japan and the rest of the world. Jpn J Clin Oncol 47(7):583–589. https://doi.org/10.1093/jjco/hyx044 CrossRefPubMed

13.

R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. https://www.r-project.org/. Accessed 22 Dec 2017

14.

Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24(31):4991–4997. https://doi.org/10.1200/jco.2006.06.8429 CrossRefPubMed

15.

Al-Batran SE, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26(9):1435–1442. https://doi.org/10.1200/jco.2007.13.9378 CrossRefPubMed

16.

Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215–221. https://doi.org/10.1016/s1470-2045(08)70035-4 CrossRefPubMed

17.

Boku N, Yamamoto S, Fukuda H et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10(11):1063–1069. https://doi.org/10.1016/s1470-2045(09)70259-1 CrossRefPubMed

18.

Ajani JA, Rodriguez W, Bodoky G et al (2010) Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28(9):1547–1553. https://doi.org/10.1200/jco.2009.25.4706 CrossRefPubMed

19.

Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697. https://doi.org/10.1016/s0140-6736(10)61121-x CrossRefPubMed

20.

Narahara H, Iishi H, Imamura H et al (2011) Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 14(1):72–80. https://doi.org/10.1007/s10120-011-0009-5 CrossRefPubMedPubMedCentral

21.

Ohtsu A, Shah MA, Van Cutsem E et al (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29(30):3968–3976. https://doi.org/10.1200/jco.2011.36.2236 CrossRefPubMed

22.

Lordick F, Kang YK, Chung HC et al (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14(6):490–499. https://doi.org/10.1016/s1470-2045(13)70102-5 CrossRefPubMed

23.

Guimbaud R, Louvet C, Ries P et al (2014) Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol 32(31):3520–3526. https://doi.org/10.1200/jco.2013.54.1011 CrossRefPubMed

24.

Koizumi W, Kim YH, Fujii M et al (2014) Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol 140(2):319–328. https://doi.org/10.1007/s00432-013-1563-5 CrossRefPubMed

25.

Ochenduszko S, Puskulluoglu M, Konopka K et al (2015) Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. Med Oncol 32(10):242. https://doi.org/10.1007/s12032-015-0687-7 CrossRefPubMedPubMedCentral

26.

Ryu MH, Baba E, Lee KH et al (2015) Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). Ann Oncol 26(10):2097–2101. https://doi.org/10.1093/annonc/mdv316 CrossRefPubMed

27.

Shen L, Li J, Xu J et al (2015) Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer 18(1):168–176. https://doi.org/10.1007/s10120-014-0351-5 CrossRefPubMed

28.

Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 26(1):141–148. https://doi.org/10.1093/annonc/mdu472 CrossRefPubMed

29.

Ohtsu A, Ajani JA, Bai YX et al (2013) Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 31(31):3935–3943. https://doi.org/10.1200/jco.2012.48.3552 CrossRefPubMedPubMedCentral

30.

Higuchi K, Tanabe S, Shimada K et al (2014) Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). Eur J Cancer 50(8):1437–1445. https://doi.org/10.1016/j.ejca.2014.01.020 CrossRefPubMed

31.

Satoh T, Xu RH, Chung HC et al (2014) Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study. J Clin Oncol 32(19):2039–2049. https://doi.org/10.1200/jco.2013.53.6136 CrossRefPubMed

32.

Nishikawa K, Fujitani K, Inagaki H et al (2015) Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. Eur J Cancer 51(7):808–816. https://doi.org/10.1016/j.ejca.2015.02.009 CrossRefPubMed

33.

Tanabe K, Fujii M, Nishikawa K et al (2015) Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05). Ann Oncol 26(9):1916–1922. https://doi.org/10.1093/annonc/mdv265 CrossRefPubMed

34.

Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36–46. https://doi.org/10.1056/NEJMoa073149 CrossRefPubMed

35.

Dank M, Zaluski J, Barone C et al (2008) Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19(8):1450–1457. https://doi.org/10.1093/annonc/mdn166 CrossRefPubMed

36.

Kang YK, Kang WK, Shin DB et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20(4):666–673. https://doi.org/10.1093/annonc/mdn717 CrossRefPubMed

37.

Lee KH, Hyun MS, Kim HK et al (2009) Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. Cancer Res Treat 41(1):12–18. https://doi.org/10.4143/crt.2009.41.1.12 CrossRefPubMedPubMedCentral

38.

Shirao K, Boku N, Yamada Y et al (2013) Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol 43(10):972–980. https://doi.org/10.1093/jjco/hyt114 CrossRefPubMed

39.

Waddell T, Chau I, Cunningham D et al (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 14(6):481–489. https://doi.org/10.1016/s1470-2045(13)70096-2 CrossRefPubMedPubMedCentral

40.

Hecht JR, Bang Y-J, Qin S, Chung H-C, Xu J-M, Park JO (2013) Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): the TRIO-013/LOGiC Trial. J Clin Oncol 34(5):suppl; abstr LBA4001. https://doi.org/10.1200/jco.2013.31.18_suppl.lba4001 CrossRef

41.

Xu R-h, Sun G-p, Lu H-s, Peng LY, Xu J-m, Zhong M-z (2013) A phase III study of S-1 plus cisplatin versus fluorouracil plus cisplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 31(15):suppl 4025–4025. https://doi.org/10.1200/jco.2013.31.15_suppl.4025 CrossRef

42.

Li J, Qin S, Xu J et al (2014) Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial. Ann Oncol 25(suppl_2):ii117. https://doi.org/10.1093/annonc/mdu193.29 CrossRef

43.

Ajani JA, Abramov M, Bondar V, Bondarenko I, Shparyk YV (2015) Untreated metastatic diffuse gastric adenocarcinoma (DGAC): randomized phase III study of S-1 and cisplatin vs. 5-FU and cisplatin (the DIGEST trial). J Clin Oncol 33(15):suppl 4015–4015. https://doi.org/10.1200/jco.2015.33.15_suppl.4015 CrossRef

44.

Cunningham D, Tebbutt NC, Davidenko I, Murad AM, Al-Batran S-E (2015) Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol 33(15):suppl 4000–4000. https://doi.org/10.1200/jco.2015.33.15_suppl.4000 CrossRef

45.

Hwang IG, Lee HR, Lee HY, Ji JH, Kang JH, Lee SI (2015) First-line capecitabine (X) monotherapy versus capecitabine plus oxaliplatin (XELOX) in elderly patients with advanced gastric cancer (AGC): results from the first interim analysis. J Clin Oncol 33(15):suppl 4051–4051. https://doi.org/10.1200/jco.2015.33.15_suppl.4051 CrossRef

46.

Nishikawa K, Yoshino S, Morita S, Takahashi T, Sakata K, Nagao J (2015) A randomized phase III study of S-1 alone versus S-1 plus immunomodulator lentinan for unresectable or recurrent gastric cancer (JFMC36–0701). Eur J Cancer 51(Supplement 3):S442CrossRef

47.

Japanese Gastric Cancer Association (2017) Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 20:1–19. https://doi.org/10.1007/s10120-016-0622-4 CrossRef

Title: Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis
Authors: Sakura Iizumi
Atsuo Takashima
Kentaro Sakamaki
Satoshi Morita
Narikazu Boku
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3569-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1)

Antiproteinuric effects of renin–angiotensin inhibitors in lung cancer patients receiving bevacizumab

A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer

Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer

A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study

Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer